Clin Mol Hepatol.
2017 Dec;23(4):311-313. 10.3350/cmh.2017.0069.
Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
- Affiliations
-
- 1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. pindra@empal.com, JHLeeMD@gmail.com
- KMID: 2406038
- DOI: http://doi.org/10.3350/cmh.2017.0069
Abstract
- No abstract available.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Entecavir 1 mg therapy for lamivudine-refractory chronic hepatitis B
- Management of Antiviral-Resistant Chronic Hepatitis B Virus Infection
- Maintaining Antiviral Efficacy after Switching to Generic Entecavir 1 mg for Antiviral-resistant Chronic Hepatitis B
- Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
- Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response
